RLBN1127



NAME OF DRUG : RLBN1127

ALSO KNOWN AS : RLBN1127

LABORATORY : RELBURN

STATUS AND ADVANCEMENT

Type of drug : Bifonctional Urates Inhibitors

Clinical trials advancement : Preclinic

Estimated time to market : 136 months.

LABORATORY ABSTRACT ON THE DRUG

For more than 50 years, elevated uric acid has been treated with a drug that reduces its production via inhibition of an enzyme, xanthine oxidase. However, almost 75% of patients in randomized Phase 3 clinical do not respond to these drugs. In such patients, a second drug has been added onto the first drug, which increases urinary excretion of uric acid by inhibiting another enzyme, URAT1. Nonetheless, this dual therapy still yields a clinical failure rate of approximately 50%.
In our discovery research, Relburn found that marked uric acid reduction with RLBN1001 owed to bifunctional inhibition of both enzyme targets – a unique effect never before described. Equally important, the inhibitory level of RLBN1001 and its novel derivatives against each target exceeded the standard agents that inhibited only a single target. We believe this highly potent activity will considerably improve clinical response rates, as well as provide substantial benefit to patients with inflammatory diseases.
A subgroup of NASH patients (30% to 50%) have elevated serum uric acid (UA).  In such patients, serum UA has shown a “dose:effect correlation” with NASH: namely, higher UA levels are clearly linked to a higher risk of developing NASH from fatty liver, as well the severity and progression of NASH to cirrhosis.

With additional laboratory studies, this association – observed over the last 15 years – has suggested that UA may actually be causative in some NASH patients. Recent studies have also shown that drugs that block UA production and/or accelerate its excretion can inhibit both development and progression of NASH. These results have prompted calls for clinical trials of potent hypouricemic drugs in NASH.

Relburn plans to test its unique drugs in clinical trials of patients afflicted with NASH in the setting of hyperuricemia.

HISTORY AND ANALYSIS

The NASH clinical candidate is now RLBN1127 derivatized from the RLBN1001

 

RECENT NEWS ON RLBN1127

2017-10-11 : Relburn-Metabolomics to Present Developments in Lead Programs for NASH and Gout

2017-10-06 : Relburn-Metabolomics Appoints Renowned Experts in Nonalcoholic Steatohepatitis (NASH) to its Scientific Advisory Board

SOME PUBLICATIONS RELATED WITH RLBN1127

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH RLBN1127


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE